You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

73 Results
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Curative, Palliative
Feb 2021
Regimen
Cancer Type:
Genitourinary, 
Testis
Intent: Curative, Adjuvant
Sep 2017
Regimen
Cancer Type:
Lung, 
Non-Small Cell, 
Small Cell
Intent: Neoadjuvant, Adjuvant, Curative, Palliative
May 2019
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Intent: Curative
Oct 2017
Regimen
Cancer Type:
Lung, 
Mesothelioma (Pleural)
Intent: Curative, Palliative
Oct 2024
Regimen
Cancer Type:
Genitourinary, 
Testis
Intent: Adjuvant, Curative
May 2019
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Adjuvant, Curative
Jan 2024
Regimen
Cancer Type:
Sarcoma, 
Desmoid Tumour
Intent: Curative
Jun 2019
Regimen
Cancer Type:
Sarcoma, 
Desmoid Tumour
Intent: Curative
Aug 2019
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Neoadjuvant, Curative
Jun 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    prednisone
Jul 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    prednisone
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - HIV-Related Aggressive Histology B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - HIV-Related Aggressive Histology B-cell Lymphoma
Jan 2024

Pages